Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Overweight: full-pipeline trial registry
50 of 198 indexed Overweight trials are currently recruiting.
Corpus placement: #52 of 28,707 conditions by registered trial count.
198 US clinical trials · 50 currently recruiting · #52 of 28,707 conditions by registered trial count
Overweight: 198 US clinical trials tracked, 50 recruiting.
Overweight is the subject of 198 registered US clinical trials on ClinicalTrials.gov, 50 of them currently open to new participants. 37 are in Phase 3-4 (later-stage) and 46 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 37 of these trials.
Enrollment posture brief
Registry condition overweight
OPEN 50 | RECR 25% | LATE 37 | EARLY 46 | RANK #52 | SPON 37
Volume-matched condition peers
Nearest open-share peer: Low Back Pain (25% recruiting · 123 trials)
Overweight lists 50 open slots (25% of 198 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Overweight on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Overweight is recruiting below its size-band peers.
50 of 198 indexed trials (25.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Overweight research.
Eli Lilly and Company accounts for 37 of 198 trials (18.7%). 94 distinct sponsors appear on at least one study for this condition label.
-
Typical Overweight enrolment sits around 120 participants.
Median target enrolment is 120 among the 198 trials that report a genuine target (sentinel values excluded). 89 of those (44.9%) plan for fewer than 100 participants.
-
Overweight research is mostly interventional.
182 interventional and 16 observational studies make up this index (91.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
198 total, page 1 of 4
International Weight Control Registry
Tufts University
NCT04907396
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
NCT07037433
Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study
Duke University
NCT06595251
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly and Company
NCT07321886
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Kailera
NCT07284875
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
Memorial Sloan Kettering Cancer Center
NCT05770570
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
NCT06143956
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Eli Lilly and Company
NCT06993792
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
NCT07282600
Community Park-Based Programs for Health Promotion: Active Older Adults Prospective Cohort Study
Duke University
NCT06604650
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company
NCT07392190
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
NCT07369011
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Eli Lilly and Company
NCT06972459
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company
NCT06972472
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Eli Lilly and Company
NCT07357415
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly and Company
NCT07035093
Avoid and Resist Strategies for Weight Management
Cedars-Sinai Medical Center
NCT05143931
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S
NCT07253285
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
University of Pittsburgh
NCT05655936
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
Novo Nordisk A/S
NCT07395687
HealthyTogether: RCT of a Dyadic Weight Management Intervention
VA Office of Research and Development
NCT06619041
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Eli Lilly and Company
NCT07232719
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
Novo Nordisk A/S
NCT07184632
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Eli Lilly and Company
NCT06945419
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Eli Lilly and Company
NCT07215559
Semaglutide for Post-Smoking Cessation Weight Management
The University of Texas Health Science Center, Houston
NCT06173778
Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients
Nitinotes Surgical
NCT07090005
Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers
Salk Institute for Biological Studies
NCT06891352
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Novo Nordisk A/S
NCT06719011
Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NCT03407079
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Eli Lilly and Company
NCT06672549
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Eli Lilly and Company
NCT06672939
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
Eli Lilly and Company
NCT07232732
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT06044935
A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity
Novo Nordisk A/S
NCT07437079
Time Restricted Feeding, Muscle, and Metabolism
University of Arkansas, Fayetteville
NCT04949451
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Eli Lilly and Company
NCT07225556
Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure
Georgia State University
NCT06735599
Night Owl Metabolism
Johns Hopkins University
NCT06507722
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
Stanford University
NCT05912621
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Shanghai World Leader Pharmaceutical Co.
NCT07465965
Improving Glycemic Control With Electrical Stimulation
University of Texas, El Paso
NCT03947697
In-Person Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes
Cornell University
NCT06557317
A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity.
Pfizer
NCT07400679
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
Roswell Park Cancer Institute
NCT03880422
Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT06325722
Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes
Georgia State University
NCT06735651
Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population
Massachusetts General Hospital
NCT05799222
The Influence of Honey-flavored Yogurt on Low-grade Inflammation and Gut Health in Middle to Older Aged Women.
University of California, Davis
NCT04248127
Dietary Supplementation on Fat Oxidation
Brightseed
NCT06548048
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 25 |
| Phase 3 | 36 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Overweight records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Overweight trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Overweight page
198 registered trials, 50 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 50 Overweight trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Overweight trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Overweight condition card totals 198 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.